Sponsored Sessions
Sponsored Sessions
Thursday, March 1, 2018
07:30 a.m. – 08:30 a.m.
Sponsored breakfast symposium – New perspectives in testosterone therapy: What is more important? Short-term sexual improvements or long-term benefits?
Testosterone therapy in men with type 2 diabetes, sexual function, quality of life and mortality
Dr. Geoff Hackett
Update on hypogonadism and cardiovascular risk
Dr. Giovanni Corona
Importance of long-term treatment to achieve full benefits of testosterone therapy
Dr. David Edwards
10:30 a.m. -12:30 p.m.
Live surgery session
(Hospital Santa Maria)
Live surgery:
AMS™ 700
Dr. Juan Ingnacio Martinez-Salamanca, Madrid, Spain
Semi Live:
AMS 700 with male sling
Dr. Brian Christine, Birmingham Alabama, USA
Sub Coronal IPP under local anaesthesia
Dr. Sean Park – Seoul, South Korea
03:00 p.m. – 03:30 p.m.
Sponsored session – Treating ED: the expert’s 2.0 challenge
20 years of PDE5-Is, the successes and the areas of amelioration
Prof. Emmanuele A. Jannini (chairman and speaker)
Avanafil in ED 2.0 management: the expert focus on clinical advantages
Prof. Irwin Goldstein (speaker)
Q&A and closing remarks
Prof. E.A. Jannini and Prof. I. Goldstein
04:30 p.m. – 05:30 p.m.
Industry innovation platform
about the vision of their organization, followed by a panel discussion with the moderators and questions from the audience.
Speakers:
Jeannette Bankes, Boston Scientific
David Perry, Urotronic
Trinity Bivalacqua, Tissue Genesis
Moshe Ein-Gal, The Direx Group
Friday, March 2, 2018
11:30 a.m. – 12:30 p.m.
Spotlight discussion session
Speakers:
Michael J. Manyak, MD, FACS. Global Medical Affairs Director Urology, GlaxoSmithKline
Prof. François Giuliano, MD, PhD, Department of Physical Medicine and Rehabilitation Raymond Poincaré Hal Garches, Versailles Saint Quentin University, France
Alejandro Carvajal Obando, MD. Associate Professor, CES University, Medellin, Colombia
Juan Ignacio Martínez-Salamanca, MD. University Hospital Puerta de Hierro, Madrid, Spain
11.30 a.m. – 11.35 a.m.
Welcome and introduction
Juan Manuel Palacios
11.35 a.m. – 11.50 a.m.
How do we currently interpret the safety profile of 5-ARI + α blocker therapies from RCTs?
François Giuliano
11.50 a.m. – 12.05 p.m.
Impact of BPH treatment on sexual function: what’s new?
Michael J. Manyak
12.05 p.m. – 12.25 p.m.
Expert insights into sexual function in BPH patients treated with 5 ARI + α blockers: panel discussion and Q&A
Chair: Juan Manuel Palacios
Panellists: François Giuliano, Michael J. Manyak, Alejandro Carvajal Obando, & Juan Ignacio Martínez-Salamanca
12.25 p.m. – 12.30 p.m.
Closing remarks
Juan Manuel Palacios
12:45 p.m. – 01:45 p.m.
Live lunch time symposium – A patients journey
Patient: John Goodridge
Mr. David Ralph, Consultant Andrologist UCLH London, United Kingdom
Mr. Kamm Mann, Primary Care Physician, Winchester, United Kingdom
Saturday, March 3, 2018
09:00 a.m. – 11:00 a.m.
Nurse training session – The patients journey through erectile restoration
Pedro Vendeira MD, PhD, FECSM, President of the Portuguese Society of Andrology, Sexual Medicine and Reproduction, Oporto, Portugal
Professor Nuno Tomada Reconstructive Urologist, Faculdade de Medicina do Porto, Portugal